Abstract Introduction: The AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German
Gynecological Oncology Group) Task Force on Diagnosis and Treatment of Breast Cancer …

Purpose Neoadjuvant chemotherapy (NACT) is increasingly adopted in the therapy of breast
cancer (BC) patients with positive axillary nodes (cN+), but the reliability and feasibility of …

Importance Data on oncological outcomes after omission of axillary lymph node dissection
(ALND) in patients with breast cancer that downstages from node positive to negative with …

Importance The increasing use of neoadjuvant systemic therapy (NST) has led to substantial
pathological complete response rates in patients with initially node-positive, early breast …

Background There is no consensus on axillary management after neoadjuvant therapy
(NAT) in patients with clinically node-positive (cN+) breast cancer. To investigate current …

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is
rapidly increasing. Thanks to the screening programs in place, nearly 90% of breast cancer …

Background In node-positive (cN+) breast cancer treated with neoadjuvant systemic therapy,
combining sentinel lymph node biopsy and targeted lymph node excision, that is targeted …

The increased use of neoadjuvant chemotherapy (NACT) has changed the approach to
breast surgery. NACT allows de-escalation of surgery by both increasing breast …

Background: Each year the interdisciplinary Arbeitsgemeinschaft Gynäkologische Onkologie
(AGO), German Gynecological Oncology Group Breast Committee on Diagnosis and …

Background In cN1 patients rendered cN0 with neoadjuvant chemotherapy, the false-
negative rate of sentinel lymph node biopsy (SLNB) is< 10% when≥ 3 sentinel lymph nodes …